Vericel price target lowered to $51 from $61 at Truist

Truist analyst Richard Newitter lowered the firm’s price target on Vericel (VCEL) to $51 from $61 and keeps a Buy rating on the shares as part of a broad research note previewing Q1 results in Medical Technology. The group’s revenue and earnings are less at risk than it could be for a number of other sub-sectors, which will likely keep investors relatively interested in the space even with some tariff choppiness in the backdrop, though the firm is also bracing for cautious 2025 outlooks as companies and models will likely begin to dial-in some macro uncertainty, the analyst tells investors in a research note.